SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Third Quarter Fiscal 2017 investor conference call and webcast on Friday, February 10, 2017 at 4:30 p.m. Eastern Time.
The call and webcast will follow the release of fiscal 2017 third quarter results. A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website, www.aethlonmedical.com.
Interested parties can also access the archived replay of the call webcast at www.aethlonmedical.com in the investor relations section under events & presentations.
Conference Call Details
What: Aethlon's Third Quarter 2017 Investor Conference Call and Audio Webcast
Date: Friday, February 10, 2017
Time: 4:30 p.m. Eastern Time
Live call: 844-836-8741
Audio Replay: 412-317-0088
About Aethlon Medical, Inc.
Aethlon Medical (Nasdaq: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. The Aethlon Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens. Named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine, the Hemopurifier® has previously been administered to individuals infected with Ebola virus, Hepatitis C virus and the Human Immunodeficiency virus. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor neurological disorders. Aethlon is part of the Russell Microcap® Index. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.
Jim Frakes, CFO
858-459-7800 extension 3300
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-to-host-third-quarter-fiscal-2017-investor-call-on-february-10-2017-300402202.html
SOURCE Aethlon Medical, Inc.